Altimmune Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect nine nominees as members of the Board of Directors for one-year terms ending at the 2027 Annual Meeting.

2. 2

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending December 31, 2026.

   More detail

   The proposal seeks shareholder ratification of E&Y as the company’s independent auditor for 2026. Management frames this as both a governance opportunity for shareholders to provide feedback and an expected procedural confirmation of the Audit Committee’s selection. While ratification is non-binding, failure to ratify would trigger reconsideration by the Audit Committee and could signal shareholder concerns about audit independence, fees, or audit quality. The filing notes E&Y’s prior audit work for 2024–2025 and disclosures regarding fees and independence; management recommends a vote FOR given E&Y’s service history and the Audit Committee’s oversight and pre-approval policies. The Audit Committee retains authority to change auditors irrespective of stockholder ratification, and the company discloses audit and tax fees and that E&Y’s reports contained no qualifications for 2024 and 2025.

3. 3

   Advisory Vote on Executive Compensation

   ManagementBoard: FOR

   Non-binding advisory vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.

   More detail

   This advisory 'say-on-pay' proposal asks shareholders to approve, on a non-binding basis, the disclosed compensation of the named executive officers. Management emphasizes a pay-for-performance philosophy, a mix of cash and long-term equity, and reliance on an independent compensation consultant and peer group benchmarking. The Compensation Committee uses annual corporate objectives and an annual bonus structure with pre-defined performance thresholds; for 2025 it determined approximately 97.5% achievement of objectives. A FOR vote is recommended to indicate support for the compensation framework; the Board and Compensation Committee will consider the advisory vote results in future decisions.

4. 4

   Approval of Amendment to Certificate of Incorporation to Increase Authorized Shares

   ManagementBoard: FOR

   Approve an amendment to the Company’s Certificate of Incorporation to increase authorized shares of Common Stock from 200,000,000 to 400,000,000.

   More detail

   The Board seeks shareholder approval to increase authorized common shares to 400 million to ensure sufficient shares for future financing, equity issuance under compensation plans, and corporate transactions without needing immediate shareholder approval for each issuance. Management argues the current authorized amount (201 million total, 200 million common) is insufficient given outstanding and reserved shares under offerings and incentive plans, and that the increase is prudent to enable timely strategic actions. The amendment would grant the Board discretion to issue additional shares, which could be dilutive and could have anti-takeover effects, though the Board states no present plan to use the authority for anti-takeover purposes. Failure to approve could constrain capital-raising flexibility and adversely affect ongoing operations or strategic initiatives; approval is recommended by the Board as a governance and operational necessity.

5. 5

   Approval of Amendment to the 2019 Employee Stock Purchase Plan (ESPP

   ManagementBoard: FOR

   Approve amendment to increase shares reserved under the 2019 ESPP from 403,500 to 1,108,827 (1% of outstanding shares as of December 31, 2025).

   More detail

   Management proposes enlarging the ESPP share reserve to 1,108,827 shares to reestablish an active employee purchase program to aid recruitment and retention. The ESPP offers 85% discounted purchase pricing and six-month offering periods, designed to encourage employee ownership. Management emphasizes that as of March 1, 2026 only 2,784 shares remained reserved, making replenishment necessary. The Administrator retains flexibility over offering periods and exercise price within Section 423 compliance; approval aligns compensation and employee investment with shareholder value. The Board recommends approval, noting tax-qualified structure and plan mechanics; dilution is limited but present, and failure to approve could hurt employee morale and hiring competitiveness.

6. 6

   Authorization to Adjourn the Annual Meeting

   ManagementBoard: FOR

   Authorize the Company to adjourn the Annual Meeting to solicit additional proxies if there are insufficient votes to approve any proposals.

   More detail

   This proposal asks shareholders to permit the Board to adjourn the meeting, if necessary, to allow additional time for proxy solicitation to obtain sufficient votes to approve other proposals. Management frames this as a procedural authorization to address circumstances where initial voting fails to reach requisite thresholds. Approval provides the Board with operational flexibility and avoids the need for immediate re-filings or special meetings; however, it could also be used to delay shareholder decisions and further solicit favorable votes. The Board recommends approval to ensure it can pursue additional outreach and secure needed approvals within a reasonable timeframe.

Upcoming shareholder meetings at Altimmune Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Altimmune Inc 2026 annual meeting?

Altimmune Inc (ALT) holds its 2026 annual shareholder meeting on Thursday, April 16, 2026.

What is the record date for the Altimmune Inc 2026 meeting?

The record date for the Altimmune Inc 2026 meeting is Friday, March 13, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Altimmune Inc's 2026 meeting?

The board is presenting 9 director nominees at the Altimmune Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Altimmune Inc 2026 meeting?

Shareholders will vote on 6 proposals at the Altimmune Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.